|
- Pfizer finalizes Metsera buy after contentious Novo bidding war
The finished deal caps a whirlwind two weeks in which Novo Nordisk attempted to swoop in and snatch the startup from under Pfizer’s nose
- Pfizer completes up to $10 billion acquisition of Metsera
Nov 13 (Reuters) - Pfizer (PFE N) on Thursday closed its up to $10 billion acquisition of Metsera (MTSR O) after winning shareholder approval, gaining a foothold in the fast-growing obesity
- Pfizer buys Metsera for $10B after obesity drug bidding war - MSN
Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated contest for the biotech firm The deal, finalized after Novo Nordisk
- Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
But for more than a week, a bidding war drove up the price to Pfizer’s final offer Pfizer won out because it was able to offer one thing Novo couldn’t: regulatory certainty Analysts, and Metsera itself, concluded that Novo’s $10 billion offer would likely take about two years to clear regulatory review
- Pfizer wins major $10B Metsera deal, beats out Novo Nordisk | Fox Business
Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, beating Danish rival Novo Nordisk following a fierce bidding war
- Pfizer wins bidding war for Metsera with $10B offer
Metsera has abandoned a deal with Novo Nordisk in favor of a new acquisition offer from Pfizer, ending a high-stakes fight between two large pharmaceutical companies over ownership of a coveted maker of obesity drugs
- Pfizer to acquire obesity drug startup Metsera in $10 billion deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy
- Pfizer to Buy Metsera for $10 Billion, Capping Bidding War
Pfizer Inc agreed to buy Metsera Inc for up to $10 billion, prevailing over Novo Nordisk A S in a bidding war Pfizer raised its offer to as much as $86 25 a share, with $65 60 a
|
|
|